KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Free Cash Flow (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Free Cash Flow data on record, last reported at $127.6 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 136.48% year-over-year to $127.6 million; the TTM value through Dec 2025 reached -$307.5 million, up 10.3%, while the annual FY2025 figure was -$307.5 million, 10.3% up from the prior year.
  • Free Cash Flow reached $127.6 million in Q4 2025 per SRPT's latest filing, up from -$37.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $229.5 million in Q2 2025 and bottomed at -$627.1 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$103.3 million, with a median of -$103.5 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: plummeted 218.27% in 2022, then surged 1713.64% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$31.5 million in 2021, then tumbled by 218.27% to -$100.4 million in 2022, then rose by 26.57% to -$73.7 million in 2023, then surged by 173.23% to $54.0 million in 2024, then skyrocketed by 136.48% to $127.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $127.6 million in Q4 2025, -$37.5 million in Q3 2025, and $229.5 million in Q2 2025.